Revolution Medicines, Inc. (RVMD)
NASDAQ
Closed
Oct 8, 2026
Day's Range
180.5152 wk Range
46.16Overview - RVMD - Revolution Medicines, Inc.
Key Statistics
Valuation
Enterprise Value
41.54B
P/E (Trailing)
‪-34.74‬
P/E (Forward)
‪-34.57‬
PEG Ratio
‪-0.26‬
Price / Book
‪16.98‬
EV / EBITDA
‪-25.67‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-30.12%‬
Return on Equity
‪-79.08%‬
Ownership
Shares Outstanding
214.24M
Float
184.49M
Short % of Shares Outstanding
‪4.76%‬
Held by Insiders
‪1.85%‬
Held by Institutions
‪100.98%‬
Price stats
Beta
‪1.40‬
50-Day Avg
‪202.03‬
200-Day Avg
‪145.29‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
23 analysts
Average price target
‪$ 248.77‬Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - RVMD - Revolution Medicines, Inc.
Peers - RVMD - Revolution Medicines, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- RVMDNASDAQRevolution Medicines, Inc.44.29BMarket Cap+77.46%52-week change-34.74P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - RVMD - Revolution Medicines, Inc.
About
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The company applies proprietary drug discovery capabilities to create small-molecule medicines designed to act on challenging RAS pathway targets, a central driver in many…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
